(CercleFinance.com) – The Janssen Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study showed that Carvykti (Cilta-cel) reduced the risk of disease progression or death by 74% versus two standard-of-care treatments in adults with relapsed, lenalidomide-refractory multiple myeloma.
“Cilta-cel has demonstrated a remarkably high level of efficacy in the latest lines of treatment, and these latest data also show its potential in the first lines,” said Binod Dhakal, associate professor and study investigator.
“The results clearly demonstrate the effectiveness of Cilta-cel when administered earlier in a patient’s treatment journey,” said Jordan Schecter, MD, vice president, Janssen Research & Development.
“Carvykti represents an important therapy in our approach to redefining the treatment of multiple myeloma,” said Jordan Schecter, MD, vice president, Janssen.
On May 25, 2023, Janssen submitted a Type II variation application to the European Medicines Agency based on the results of the study for approval of Carvykti for the treatment of patients with relapsed and refractory multiple myeloma. lenalidomide.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
